Nonhuman Primate Model for Preclinical Evaluation of Haplotype-Based iPSC Banking for HLA-matched Blood Products
用于 HLA 匹配血液制品基于单倍型 iPSC 库的临床前评估的非人灵长类动物模型
基本信息
- 批准号:9153287
- 负责人:
- 金额:$ 60.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-01 至 2020-04-30
- 项目状态:已结题
- 来源:
- 关键词:AlloimmunizationAnimal ModelAnimalsAntibody ResponseApplications GrantsAutologousBlood CellsBlood typing procedureBone Marrow SuppressionBone Marrow TransplantationCD34 geneCell LineCell TherapyCell TransplantsCellsClinicClinicalClinical TrialsEnrollmentEvaluationExperimental ModelsFoundationsFounder GenerationFutureGenetic ScreeningGoalsHaplotypesHematological DiseaseHematopoieticHistocompatibilityHistocompatibility TestingHumanImmuneMacacaMajor Histocompatibility ComplexMeasuresModelingMyelosuppressionPTPRC genePopulationPre-Clinical ModelProductionResearchRiskSafetyStem cell transplantStem cellsTestingTransfusionTranslationsTransplantationTreatment Efficacyabstractingbaseblood groupblood productcell bankclinical efficacycostcytopeniadesignhuman diseaseimmunogenicityin vivoinduced pluripotent stem cellnonhuman primatenovelpreclinical evaluationprogenitorpublic health relevanceresponsescale upstem cell therapy
项目摘要
Project Summary/Abstract
Recent advances in hematopoietic differentiation from human induced pluripotent stem cells (iPSCs) have
brought the clinical translation of iPSC-derived blood products closer to reality and highlight the need for the
developing of novel animal models for preclinical evaluation of the efficacy, safety, and immunogenicity of
iPSC-derived blood products. Because iPSCs can be derived from the intended recipient, they offer the
possibility to generate autologous blood cells in unlimited numbers and avoid HLA alloimmunization. However,
the high costs of personalized stem cell therapy and its complexity makes it currently impractical for broad
application. Creation of iPSC banks has been proposed as an approach to supply HLA-matched blood cells.
Yet, iPSC banking using random donors would remain impractical due to the high variability of HLA. The
banking iPSCs from HLA-homozygous donors (haplotype-based banking strategy) has been suggested to be
an effective way to provide a scalable off-the-shelf supply of immunologically compatible cells for cellular
therapies and maximize the utility of stem cell banking. Thus, developing experimental models for banking HLA
homozygous iPSC lines and assessing their immunogenicity, therapeutic efficacy, and safety will be essential
to the future design and utility of stem cell banks for manufacturing HLA-compatible blood products. Here, we
propose to establish a nonhuman primate model for banking major histocompatibility (MHC) homozygous iPSC
lines for transfusion therapies. The proposed model will employ Mauritian cynomolgus macaques, which are
descendent from a small founder population and have very limited MHC diversity consisting of only seven
common haplotypes (M1-M7). This provides a unique opportunity to rapidly select MHC homozygous and MHC
and blood group-identical animals or animals with well-defined MHC mismatches by genetic screening. We will
use this model to evaluate the utility and safety of MHC homozygous iPSC-derived CD34+CD45+CD38-
multipotent hematopoietic progenitors in the treatment of cytopenia following myeloablative stem cell
transplantation and test the hypothesis that transfusion of imHPs derived from MHC-matched homozygous
iPSCs reduces HLA alloimmunization. In aim 1, we will establish a MHC homozygous NHP model for
preclinical evaluation of MHC compatible iPSC-derived blood products. In aim 2, we will evaluate the efficacy
and safety of MHC homozygous iPSC-based therapies for acquired bone marrow suppression in MCM model.
In aim 3, we will assess the alloimmune responses toward MHC homozygous imHPs following transfer across
MHC barriers. Overall, the proposed research will demonstrate the utility and safety of using MHC
homozygous iPSC-derived hematopoietic cells for the treatment of myelosuppression and HLA
alloimmunization reduction.
项目总结/摘要
从人诱导的多能干细胞(iPSC)造血分化的最新进展已经
使iPSC衍生血液制品的临床转化更接近现实,并强调了
开发新型动物模型,用于临床前评价的有效性,安全性和免疫原性
iPSC衍生的血液制品。因为iPSC可以从预期的接受者中获得,所以它们提供了
产生无限数量的自体血细胞的可能性,并避免HLA同种异体免疫。然而,在这方面,
个体化干细胞治疗的高成本及其复杂性使得其目前对于广泛应用是不切实际的。
应用程序.已提出创建iPSC库作为提供HLA匹配血细胞的一种方法。
然而,由于HLA的高变异性,使用随机供体的iPSC库仍然是不切实际的。的
从HLA纯合供体中储存iPSC(基于单体型的储存策略)已被认为是
为细胞提供可扩展的现成免疫相容细胞供应的有效方法
最大限度地发挥干细胞库的效用。因此,开发银行HLA实验模型
纯合iPSC系,并评估其免疫原性、治疗效果和安全性将是至关重要的
涉及用于制造HLA相容性血液制品的干细胞库的未来设计和应用。这里我们
建议建立非人灵长类动物模型,用于储存主要组织相容性(MHC)纯合iPSC
输血治疗的管路。所提出的模型将采用印度尼西亚食蟹猴,
来自一个小的创始人人口的后裔,并具有非常有限的MHC多样性,仅由七个
常见单倍型(M1-M7)。这提供了一个独特的机会,快速选择MHC纯合和MHC
和血型相同的动物或通过遗传筛选具有明确的MHC错配的动物。我们将
使用该模型评估MHC纯合iPSC衍生的CD 34 + CD 45 + CD 38-
多能造血祖细胞治疗清髓性干细胞移植后血细胞减少症
移植和测试的假设,输注imHPs来自MHC匹配的纯合子
iPSC减少HLA同种异体免疫。目的一:建立MHC纯合型NHP动物模型,
MHC相容性iPSC衍生的血液制品的临床前评价。在目标2中,我们将评估疗效
和基于MHC纯合iPSC的疗法在MCM模型中用于获得性骨髓抑制的安全性。
在目标3中,我们将评估在转移至小鼠后针对MHC纯合imHP的同种免疫应答。
MHC屏障。总的来说,拟议的研究将证明使用MHC的实用性和安全性。
用于治疗骨髓抑制和HLA的纯合iPSC衍生的造血细胞
同种免疫减少。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Igor I. Slukvin其他文献
Assessment of safety and immunogenicity of MHC homozygous iPSC-derived CD34sup+/sup hematopoietic progenitors in an NHP model
- DOI:
10.1182/bloodadvances.2022006984 - 发表时间:
2022-09-27 - 期刊:
- 影响因子:7.100
- 作者:
Saritha S. D'Souza;Akhilesh Kumar;John Maufort;Jason T. Weinfurter;Matthew Raymond;Nick S. Strelchenko;Elizabeth Perrin;Jennifer Coonen;Andres Mejia;Heather A. Simmons;Bruce E. Torbett;Matthew Reynolds;James A. Thomson;Igor I. Slukvin - 通讯作者:
Igor I. Slukvin
CELLULES ÉRYTHROÏDES PRODUISANT DE L'HÉMOGLOBINE ADULTE DE TYPE β GÉNÉRÉE À PARTIR DE CELLULES SOUCHES EMBRYONNAIRES
β 型成人血红蛋白生成细胞和胚胎细胞部分
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
Igor I. Slukvin;James A. Thomson;M. Vodyanyk;Maryna E. Gumenyuk - 通讯作者:
Maryna E. Gumenyuk
Methode d'elaboration de cellules dendritiques a partir de cellules souches embryonnaires
细胞树突和胚胎细胞部分的详细阐述方法
- DOI:
- 发表时间:
2006 - 期刊:
- 影响因子:0
- 作者:
Igor I. Slukvin;James A. Thomson;M. Vodyanyk;Maryna E. Gumenyuk - 通讯作者:
Maryna E. Gumenyuk
Small-diameter artery grafts engineered from pluripotent stem cells maintain 100% patency in an allogeneic rhesus macaque model
由多能干细胞工程化的小直径动脉移植物在同种异体恒河猴模型中保持 100%的通畅率。
- DOI:
10.1016/j.xcrm.2025.102002 - 发表时间:
2025-03-18 - 期刊:
- 影响因子:10.600
- 作者:
Jue Zhang;Diana Marcela Tabima;David Vereide;Weifeng Zeng;Nicholas J. Albano;Sarah Lyon;Peter J. Nicksic;Ellen C. Shaffrey;Robert E. George;Mitchell D. Probasco;Elizabeth S. Perrin;Yiyang Xu;Matthew E. Brown;Ron Stewart;Naomi C. Chesler;Lih-Sheng Turng;Samuel O. Poore;Igor I. Slukvin;James A. Thomson;John P. Maufort - 通讯作者:
John P. Maufort
Igor I. Slukvin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Igor I. Slukvin', 18)}}的其他基金
Nonhuman Primate Model for Preclinical Evaluation of Haplotype-Based iPSC Banking for HLA-matched Blood Products
用于 HLA 匹配血液制品基于单倍型 iPSC 库的临床前评估的非人灵长类动物模型
- 批准号:
9276794 - 财政年份:2016
- 资助金额:
$ 60.12万 - 项目类别:
Transplantation of MHC Homozygous Vascular Progenitors in Primates
灵长类 MHC 纯合血管祖细胞移植
- 批准号:
10416029 - 财政年份:2016
- 资助金额:
$ 60.12万 - 项目类别:
Transplantation of MHC Homozygous Vascular Progenitors in Primates
灵长类 MHC 纯合血管祖细胞移植
- 批准号:
10181017 - 财政年份:2016
- 资助金额:
$ 60.12万 - 项目类别:
iPSC-based blood regenerative therapies for AIDS
基于 iPSC 的艾滋病血液再生疗法
- 批准号:
9057122 - 财政年份:2013
- 资助金额:
$ 60.12万 - 项目类别:
iPSC-based blood regenerative therapies for AIDS
基于 iPSC 的艾滋病血液再生疗法
- 批准号:
8708198 - 财政年份:2013
- 资助金额:
$ 60.12万 - 项目类别:
iPSC-based blood regenerative therapies for AIDS
基于 iPSC 的艾滋病血液再生疗法
- 批准号:
8603133 - 财政年份:2013
- 资助金额:
$ 60.12万 - 项目类别:
iPSC-based blood regenerative therapies for AIDS
基于 iPSC 的艾滋病血液再生疗法
- 批准号:
9268021 - 财政年份:2013
- 资助金额:
$ 60.12万 - 项目类别:
ES Cell-Specific Genes and Reprogramming of Human Somatic Cells
ES细胞特异性基因和人类体细胞重编程
- 批准号:
8381277 - 财政年份:2012
- 资助金额:
$ 60.12万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 60.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists